The company’s earnings beat estimates in each of the past four quarters with the average surprise being 36.96%. AstraZeneca PLC Price and EPS Surprise. AstraZeneca PLC price-eps-surprise | AstraZeneca PLC Quote. In the last reported quarter, AstraZeneca delivered a positive earnings surprise of 11.11%. Product sales in the third quarter benefited from favorable inventory and gross-to-net movements. However, the benefits were absent this time around. Fourth-quarter sales of Imfinzi are likely to have benefited from strong demand trends in the United States, especially in lung cancer indications. AstraZeneca’s other major drugs like Fasenra, Brilinta and Farxiga are likely to have contributed to sales growth the soon-to-be reported quarter. However, please note that increased competition and formulary plan changes for competitors’ drugs hurt sales of Farxiga in the United States in the third quarter.
1 other references
Latest Stories From Referenced Companies
Feb 21, 2020
Feb 20, 2020